September 22, 2020
Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels, data from a clinical trial led by Dana-Farber/Brigham and Women’s Cancer Center suggests. The results of the trial, dubbed the IMpassion031 study, will be presented at the […]